knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 16:24:52 - browse：2

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： As obesity drug market grows, telehealth companies court payers

Wikipedia

WSS

As obesity drug market grows, telehealth companies court payers

Alabama frozen embryo ruling has major implications for IVF clinics

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Kellogg’s is going to war over Mexico’s nutrition label rules

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

People can get long Covid without testing positive for virus: Study

focus

knowledge

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Community Health Systems hospitals under DOJ investigation

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

6 phony surgeries that take placebo to the extreme

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA greenlights medical device to combat bladder issues

Wildfire smoke exposes gaps in outdoor worker protections

CDC says it’s too soon to assess risk posed by Covid subvariant

United colonoscopy coverage change 'may cost lives,' doctors say

NIH study of ME/CFS points to clear biological hallmarks

hotspot

PBM reform efforts get punted in Congress

FDA greenlights medical device to combat bladder issues

6 phony surgeries that take placebo to the extreme

People can get long Covid without testing positive for virus: Study

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Dario to buy mental health app maker Twill in cash and stock deal

leisure time

entertainment

Wikipedia

focus